Narcolepsy, Pharmacological

Lundbeck Receives FDA Fast Track Designation for Lu Ah69593 Orexin 2 Receptor Agonist

Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company’s lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck’s development portfolio for sleep-wake disorders. Lu AH69593 was discovered by Lundbeck and it is presently in […]

Narcolepsy, Pharmacological

Takeda’s ORZEYFUL Approved in China for Narcolepsy Type 1

Takeda China announced that the National Medical Products Administration of China has approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 years and older and adults. Oveporexton is the first oral orexin receptor 2 (OX2R)-selective agonist approved in China and is the […]

Product News

FDA Cites BMC Medical Over Unapproved G3X APAP, Undisclosed Design Changes to Luna Line 

The FDA has issued a warning letter to BMC Medical Co., Ltd., the Beijing-based manufacturer behind the Luna and G3X lines of CPAP and APAP devices sold in the U.S. through distributor 3B Medical (doing business as React Health) of Dublin, Ohio. The letter, dated May 20, 2026, stems from […]

Artificial Intelligence

Patient Prism Introduces AI Revenue Platform Improving Patient Access

Healthcare providers are under growing pressure to improve patient access while facing staffing shortages and rising operational costs. Yet, many AI tools fail to deliver measurable financial results, leaving practices stuck in “pilot purgatory.” Patient Prism aims to solve these challenges with its AI Revenue Activation platform. The proprietary AI-driven […]